Hyperkalemia in Heart Failure

Chaudhry M S Sarwar, Lampros Papadimitriou, Bertram Pitt, Ileana L. Pina, Faiez Zannad, Stefan D. Anker, Mihai Gheorghiade, Javed Butler

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Disorders of potassium homeostasis can potentiate the already elevated risk of arrhythmia in heart failure. Heart failure patients have a high prevalence of chronic kidney disease, which further heightens the risk of hyperkalemia, especially when renin-angiotensin-aldosterone system inhibitors are used. Acute treatment for hyperkalemia may not be tolerated in the long term. Recent data for patiromer and sodium zirconium cyclosilicate, used to treat and prevent high serum potassium levels on a more chronic basis, have sparked interest in the treatment of hyperkalemia, as well as the potential use of renin-angiotensin-aldosterone system inhibitors in patients who were previously unable to take these drugs or tolerated only low doses. This review discusses the epidemiology, pathophysiology, and outcomes of hyperkalemia in heart failure; provides an overview of traditional and novel ways to approach management of hyperkalemia; and discusses the need for further research to optimally treat heart failure.

Original languageEnglish (US)
Pages (from-to)1575-1589
Number of pages15
JournalJournal of the American College of Cardiology
Volume68
Issue number14
DOIs
StatePublished - Oct 4 2016

Fingerprint

Hyperkalemia
Heart Failure
Renin-Angiotensin System
Potassium
Chronic Renal Insufficiency
Cardiac Arrhythmias
Epidemiology
Homeostasis
Therapeutics
Serum
Research
Pharmaceutical Preparations

Keywords

  • angiotensin-converting enzyme inhibitors
  • angiotensin-receptor blockers
  • chronic kidney disease
  • mineralocorticoid receptor antagonist
  • patiromer
  • sodium zirconium cyclosilicate

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sarwar, C. M. S., Papadimitriou, L., Pitt, B., Pina, I. L., Zannad, F., Anker, S. D., ... Butler, J. (2016). Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 68(14), 1575-1589. https://doi.org/10.1016/j.jacc.2016.06.060

Hyperkalemia in Heart Failure. / Sarwar, Chaudhry M S; Papadimitriou, Lampros; Pitt, Bertram; Pina, Ileana L.; Zannad, Faiez; Anker, Stefan D.; Gheorghiade, Mihai; Butler, Javed.

In: Journal of the American College of Cardiology, Vol. 68, No. 14, 04.10.2016, p. 1575-1589.

Research output: Contribution to journalReview article

Sarwar, CMS, Papadimitriou, L, Pitt, B, Pina, IL, Zannad, F, Anker, SD, Gheorghiade, M & Butler, J 2016, 'Hyperkalemia in Heart Failure', Journal of the American College of Cardiology, vol. 68, no. 14, pp. 1575-1589. https://doi.org/10.1016/j.jacc.2016.06.060
Sarwar CMS, Papadimitriou L, Pitt B, Pina IL, Zannad F, Anker SD et al. Hyperkalemia in Heart Failure. Journal of the American College of Cardiology. 2016 Oct 4;68(14):1575-1589. https://doi.org/10.1016/j.jacc.2016.06.060
Sarwar, Chaudhry M S ; Papadimitriou, Lampros ; Pitt, Bertram ; Pina, Ileana L. ; Zannad, Faiez ; Anker, Stefan D. ; Gheorghiade, Mihai ; Butler, Javed. / Hyperkalemia in Heart Failure. In: Journal of the American College of Cardiology. 2016 ; Vol. 68, No. 14. pp. 1575-1589.
@article{6da2e71f1f2542e0a9a0d08e381076b0,
title = "Hyperkalemia in Heart Failure",
abstract = "Disorders of potassium homeostasis can potentiate the already elevated risk of arrhythmia in heart failure. Heart failure patients have a high prevalence of chronic kidney disease, which further heightens the risk of hyperkalemia, especially when renin-angiotensin-aldosterone system inhibitors are used. Acute treatment for hyperkalemia may not be tolerated in the long term. Recent data for patiromer and sodium zirconium cyclosilicate, used to treat and prevent high serum potassium levels on a more chronic basis, have sparked interest in the treatment of hyperkalemia, as well as the potential use of renin-angiotensin-aldosterone system inhibitors in patients who were previously unable to take these drugs or tolerated only low doses. This review discusses the epidemiology, pathophysiology, and outcomes of hyperkalemia in heart failure; provides an overview of traditional and novel ways to approach management of hyperkalemia; and discusses the need for further research to optimally treat heart failure.",
keywords = "angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, chronic kidney disease, mineralocorticoid receptor antagonist, patiromer, sodium zirconium cyclosilicate",
author = "Sarwar, {Chaudhry M S} and Lampros Papadimitriou and Bertram Pitt and Pina, {Ileana L.} and Faiez Zannad and Anker, {Stefan D.} and Mihai Gheorghiade and Javed Butler",
year = "2016",
month = "10",
day = "4",
doi = "10.1016/j.jacc.2016.06.060",
language = "English (US)",
volume = "68",
pages = "1575--1589",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "14",

}

TY - JOUR

T1 - Hyperkalemia in Heart Failure

AU - Sarwar, Chaudhry M S

AU - Papadimitriou, Lampros

AU - Pitt, Bertram

AU - Pina, Ileana L.

AU - Zannad, Faiez

AU - Anker, Stefan D.

AU - Gheorghiade, Mihai

AU - Butler, Javed

PY - 2016/10/4

Y1 - 2016/10/4

N2 - Disorders of potassium homeostasis can potentiate the already elevated risk of arrhythmia in heart failure. Heart failure patients have a high prevalence of chronic kidney disease, which further heightens the risk of hyperkalemia, especially when renin-angiotensin-aldosterone system inhibitors are used. Acute treatment for hyperkalemia may not be tolerated in the long term. Recent data for patiromer and sodium zirconium cyclosilicate, used to treat and prevent high serum potassium levels on a more chronic basis, have sparked interest in the treatment of hyperkalemia, as well as the potential use of renin-angiotensin-aldosterone system inhibitors in patients who were previously unable to take these drugs or tolerated only low doses. This review discusses the epidemiology, pathophysiology, and outcomes of hyperkalemia in heart failure; provides an overview of traditional and novel ways to approach management of hyperkalemia; and discusses the need for further research to optimally treat heart failure.

AB - Disorders of potassium homeostasis can potentiate the already elevated risk of arrhythmia in heart failure. Heart failure patients have a high prevalence of chronic kidney disease, which further heightens the risk of hyperkalemia, especially when renin-angiotensin-aldosterone system inhibitors are used. Acute treatment for hyperkalemia may not be tolerated in the long term. Recent data for patiromer and sodium zirconium cyclosilicate, used to treat and prevent high serum potassium levels on a more chronic basis, have sparked interest in the treatment of hyperkalemia, as well as the potential use of renin-angiotensin-aldosterone system inhibitors in patients who were previously unable to take these drugs or tolerated only low doses. This review discusses the epidemiology, pathophysiology, and outcomes of hyperkalemia in heart failure; provides an overview of traditional and novel ways to approach management of hyperkalemia; and discusses the need for further research to optimally treat heart failure.

KW - angiotensin-converting enzyme inhibitors

KW - angiotensin-receptor blockers

KW - chronic kidney disease

KW - mineralocorticoid receptor antagonist

KW - patiromer

KW - sodium zirconium cyclosilicate

UR - http://www.scopus.com/inward/record.url?scp=84992027427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992027427&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2016.06.060

DO - 10.1016/j.jacc.2016.06.060

M3 - Review article

C2 - 27687200

AN - SCOPUS:84992027427

VL - 68

SP - 1575

EP - 1589

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 14

ER -